Rachel Ettinger

Rachel Ettinger

Auto-generated profile, based on publicly available information

Rachel Ettinger

†Viela Bio, Gaithersburg, MD 20878; and

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
SWShu Wang
Shu Wang
JWJingya Wang
Jingya Wang
VKVarsha Kumar
Varsha Kumar
JKJodi L Karnell
Jodi L Karnell
BNBrian Naiman
Brian Naiman
RERachel Ettinger
Rachel Ettinger
Although the aetiology of systemic lupus erythematosus (SLE) is unclear, dysregulated B cell responses have been implicated. Here we show that an unusual CD11chiT-bet+ B cell subset, with a unique expression profile including chemokine receptors consistent with migration to target tissues, is expanded in SLE patients, present in nephrotic kidney, enriched for autoreactive specificities and correlates with defined clinical manifestations. IL-21 can potently induce CD11chiT-bet+ B cells and promote the differentiation of these cells into Ig-secreting autoreactive plasma cells. While murine studies have identified a role for T-bet-expressing B cells in autoimmunity, this study describes and exemplifies the importance of CD11chiT-bet+ B cells in human SLE.

1 February 2019 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
JKJodi L. Karnell
Jodi L. Karnell
SRSadiye Amcaoglu Rieder
Sadiye Amcaoglu Rieder
RERachel Ettinger
Rachel Ettinger
RKRoland Kolbeck
Roland Kolbeck
CD40 is a TNF receptor superfamily member expressed on both immune and non-immune cells. Interactions between B cell-expressed CD40 and its binding partner, CD40L, predominantly expressed on activated CD4+ T cells, play a critical role in promoting germinal center formation and the production of class-switched antibodies. Non-hematopoietic cells expressing CD40 can also engage CD40L and trigger a pro-inflammatory response. This article will highlight what is known about the biology of the CD40-CD40L axis in humans and describe the potential contribution of CD40 signaling on both hematopoietic and non-hematopoietic cells to autoimmune disease pathogenesis. Additionally, novel therapeutic approaches to target this pathway, currently being evaluated in clinical trials, are discussed.

1 June 2008 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
RERachel Ettinger
Rachel Ettinger
SKStefan Kuchen
Stefan Kuchen
PLPeter E. Lipsky
Peter E. Lipsky

1 November 2017 in Cellular Immunology
Verified
Journal Article
Open access
JKJodi L. Karnell
Jodi L. Karnell
VKVarsha Kumar
Varsha Kumar
JWJingya Wang
Jingya Wang
SWShu Wang
Shu Wang
Elisaveta VoynovaElisaveta Voynova
Elisaveta Voynova
RERachel Ettinger
Rachel Ettinger
A growing body of evidence suggests that when B cells are chronically stimulated, a phenotypically unique subset expands. Data suggest that this atypical population contains B cell receptor (BCR) specificities capable of binding the antigen, or sets of antigens that initiated the expansion of these cells. These B cells have been given various names, including double negative B cells, atypical memory B cells, tissue-like memory B cells, or age associated B cells (ABCs). However, on close inspection these reports described B cell subsets that closely resemble B cells we refer to as CD11c+ B cells that often express T-bet. Here we will review the human studies that describe atypical memory B cells and compare and contrast their phenotype and suggested function in health and disease.

3 April 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SPSantosh K. Panda
Santosh K. Panda
VFValeria Facchinetti
Valeria Facchinetti
Elisaveta VoynovaElisaveta Voynova
Elisaveta Voynova
SHShino Hanabuchi
Shino Hanabuchi
JKJodi L. Karnell
Jodi L. Karnell
YLYong-Jun Liu
Yong-Jun Liu
Uncontrolled secretion of type I IFN, as the result of endosomal TLR (i.e., TLR7 and TLR9) signaling in plasmacytoid DCs (pDCs), and abnormal production of autoantibodies by B cells are critical for systemic lupus erythematosus (SLE) pathogenesis. The importance of galectin-9 (Gal-9) in regulating various autoimmune diseases, including lupus, has been demonstrated. However, the precise mechanism by which Gal-9 mediates this effect remains unclear. Here, using spontaneous murine models of lupus (i.e., BXSB/MpJ and NZB/W F1 mice), we demonstrate that administration of Gal-9 results in reduced TLR7-mediated autoimmune manifestations. While investigating the mechanism underlying this phenomenon, we observed that Gal-9 inhibits the phenotypic maturation of pDCs and B cells and abrogates their ability to mount cytokine responses to TLR7/TLR9 ligands. Importantly, immunocomplex-mediated (IC-mediated) and neutrophil extracellular trap–mediated (NET-mediated) pDC activation was inhibited by Gal-9. Additionally, the mTOR/p70S6K pathway, which is recruited by both pDCs and B cells for TLR-mediated IFN secretion and autoantibody generation, respectively, was attenuated. Gal-9 was found to exert its inhibitory effect on both the cells by interacting with CD44.

1 December 2008 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
RER Ettinger
R Ettinger
SKS Kuchen
S Kuchen
PLP E Lipsky
P E Lipsky
Interleukin 21 (IL21) belongs to a family of cytokines that bind to a composite receptor consisting of a private receptor (IL21R) and the common cytokine receptor γ chain (γC). The IL21R is widely distributed on lympho-haematopoietic cells and IL21 impacts a number of cell types, including CD8+ memory T cells, NK cells and subsets of CD4 memory T cells. One essential role of IL21 is the promotion of B-cell activation and differentiation or death during humoral immune responses. Increased IL21 production is characteristic of certain autoimmune diseases and is likely to contribute to autoantibody production as well as pathological features of autoimmune disease. The critical role of IL21 in promoting humoral immune responses makes it an important focus of potential therapeutic interventions in conditions characterised by overproduction of pathogenic autoantibodies.